Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Multi-Center Study Comparing Prolonged Primary Systemic Endocrine Therapy With Letrozole Alone or in Combination With Zoledronic Acid in Early Breast Cancer (NEOadjuvant Study in CANada)

NCT00247650 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00247650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00247650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Multi-Center Study Comparing Prolonged Primary Systemic Endocrine Therapy With Letrozole Alone or in Combination With Zoledronic Acid in Early Breast Cancer (NEOadjuvant Study in CANada)
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
Not reported
Enrollment
190 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer